2. Biktarvy


Active ingredients: bictegravir  
Disease: HIV  
Peak sales estimate: $6 billion  
Approved: Feb. 7, 2018
Company: Gilead Sciences 

The scoop: Facing mounting pressure on its critical hepatitis C business, Gilead Sciences won a timely FDA nod for HIV combo drug Biktarvy in February. The drug, which will face off in the field against GlaxoSmithKline’s ViiV Healthcare and its new Juluca, carries blockbuster commercial expectations. Consensus estimates are for $6 billion in peak sales, but one analyst predicts the drug could generate as much as $10 billion. Biktarvy combines the novel integrase inhibitor bictegravir with Gilead's own Descovy, a combo of emtricitabine and tenofovir alafenamide. The approval comes as Gilead’s hep C franchise comes under increasing competitive pressure, hurting Gilead’s pricing power in the field.  — Eric Sagonowsky

2. Biktarvy

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.